Keywords: Daiichi Sankyo, Roxro Pharma, Luitpold, M&A, SPRIX, Acute pain
Daiichi Sankyo US unit buys Roxro Pharma to gain pain drug SPRIX
Article | 14 December 2010
Luitpold Pharmaceuticals, a New York, USA-based subsidiary of Japanese drug major Daiichi Sankyo (TKO: 4568), has signed a binding merger agreement ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
